These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30414384)

  • 41. Over-ruling a group sequential boundary--a stopping rule versus a guideline.
    Lan KK; Lachin JM; Bautista O
    Stat Med; 2003 Nov; 22(21):3347-55. PubMed ID: 14566919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimization of adaptive designs: efficiency evaluation.
    Menon S; Chang M
    J Biopharm Stat; 2012; 22(4):641-61. PubMed ID: 22651106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symmetric group sequential test designs.
    Emerson SS; Fleming TR
    Biometrics; 1989 Sep; 45(3):905-23. PubMed ID: 2675998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An introduction to the use of interim data analyses in clinical trials.
    Lewis RJ
    Ann Emerg Med; 1993 Sep; 22(9):1463-9. PubMed ID: 8363121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized trials stopped early for benefit: a systematic review.
    Montori VM; Devereaux PJ; Adhikari NK; Burns KE; Eggert CH; Briel M; Lacchetti C; Leung TW; Darling E; Bryant DM; Bucher HC; Schünemann HJ; Meade MO; Cook DJ; Erwin PJ; Sood A; Sood R; Lo B; Thompson CA; Zhou Q; Mills E; Guyatt GH
    JAMA; 2005 Nov; 294(17):2203-9. PubMed ID: 16264162
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interim analysis: the alpha spending function approach.
    DeMets DL; Lan KK
    Stat Med; 1994 Jul 15-30; 13(13-14):1341-52; discussion 1353-6. PubMed ID: 7973215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical trials with sequential analysis that were early-stopped: How to interpret them?
    Garegnani LI; Arancibia M; Madrid E; Franco JVA
    Medwave; 2020 Jun; 20(5):e7930. PubMed ID: 32603319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A computer program for designing clinical trials with arbitrary survival curves and group sequential testing.
    Halpern J; Brown BW
    Control Clin Trials; 1993 Apr; 14(2):109-22. PubMed ID: 8500301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should Clinical Trials Be Terminated Early?
    Streiner DL
    Clin Ther; 2019 Sep; 41(9):1889-1891. PubMed ID: 31351677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequential methods and group sequential designs for comparative clinical trials.
    Sébille V; Bellissant E
    Fundam Clin Pharmacol; 2003 Oct; 17(5):505-16. PubMed ID: 14703713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monitoring a three-armed clinical trial with survival endpoints: Fisher's least significant difference approach.
    Chen PL; Dominik R
    J Biopharm Stat; 2004 Aug; 14(3):791-801. PubMed ID: 15468765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Some extensions to a new approach for interim analysis in clinical trials.
    Falissard B; Lellouch J
    Stat Med; 1991 Jun; 10(6):949-55; discussion 956-7. PubMed ID: 1876784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Online control of the False Discovery Rate in group-sequential platform trials.
    Zehetmayer S; Posch M; Koenig F
    Stat Methods Med Res; 2022 Dec; 31(12):2470-2485. PubMed ID: 36189481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incorporating intermediate binary responses into interim analyses of clinical trials: a comparison of four methods.
    Whitehead A; Sooriyarachchi MR; Whitehead J; Bolland K
    Stat Med; 2008 May; 27(10):1646-66. PubMed ID: 17886243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiplicity in randomised trials II: subgroup and interim analyses.
    Schulz KF; Grimes DA
    Lancet; 2005 May 7-13; 365(9471):1657-61. PubMed ID: 15885299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Group sequential design for historical control trials using error spending functions.
    Wu J; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):351-363. PubMed ID: 31718458
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.